Book contents
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Basic aspects of neurodegeneration
- 1 Endogenous free radicals and antioxidants in the brain
- 2 Biological oxidants and therapeutic antioxidants
- 3 Mitochondria, metabolic inhibitors and neurodegeneration
- 4 Excitoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases
- 5 Glutamate transporters
- 6 Calcium binding proteins in selective vulnerability of motor neurons
- 7 Apoptosis in neurodegenerative diseases
- 8 Neurotrophic factors
- 9 Protein misfolding and cellular defense mechanisms in neurodegenerative diseases
- 10 Neurodegenerative disease and the repair of oxidatively damaged DNA
- 11 Compounds acting on ion channels
- 12 The role of nitric oxide and PARP in neuronal cell death
- 13 Copper and zinc in Alzheimer's disease and amyotrophic lateral sclerosis
- 14 The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment
- 15 Selected genetically engineered models relevant to human neurodegenerative disease
- 16 Toxic animal models
- 17 A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders
- 18 Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus
- Part II Neuroimaging in neurodegeneration
- Part III Therapeutic approaches in neurodegeneration
- Normal aging
- Part IV Alzheimer's disease
- Part VI Other Dementias
- Part VII Parkinson's and related movement disorders
- Part VIII Cerebellar degenerations
- Part IX Motor neuron diseases
- Part X Other neurodegenerative diseases
- Index
- References
5 - Glutamate transporters
from Part I - Basic aspects of neurodegeneration
Published online by Cambridge University Press: 04 August 2010
- Frontmatter
- Contents
- List of contributors
- Preface
- Part I Basic aspects of neurodegeneration
- 1 Endogenous free radicals and antioxidants in the brain
- 2 Biological oxidants and therapeutic antioxidants
- 3 Mitochondria, metabolic inhibitors and neurodegeneration
- 4 Excitoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases
- 5 Glutamate transporters
- 6 Calcium binding proteins in selective vulnerability of motor neurons
- 7 Apoptosis in neurodegenerative diseases
- 8 Neurotrophic factors
- 9 Protein misfolding and cellular defense mechanisms in neurodegenerative diseases
- 10 Neurodegenerative disease and the repair of oxidatively damaged DNA
- 11 Compounds acting on ion channels
- 12 The role of nitric oxide and PARP in neuronal cell death
- 13 Copper and zinc in Alzheimer's disease and amyotrophic lateral sclerosis
- 14 The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment
- 15 Selected genetically engineered models relevant to human neurodegenerative disease
- 16 Toxic animal models
- 17 A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders
- 18 Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus
- Part II Neuroimaging in neurodegeneration
- Part III Therapeutic approaches in neurodegeneration
- Normal aging
- Part IV Alzheimer's disease
- Part VI Other Dementias
- Part VII Parkinson's and related movement disorders
- Part VIII Cerebellar degenerations
- Part IX Motor neuron diseases
- Part X Other neurodegenerative diseases
- Index
- References
Summary
Introduction
In the central nervous system (CNS) of mammals, glutamate acts as a chemical transmitter of excitatory signals by binding to different glutamate receptors and activating a multitude of highly integrated molecular pathways. Termination of this excitatory neurotransmission occurs via re-uptake of glutamate by specialized high affinity transporters capable of maintaining glutamate at ∼1 μM levels in the synaptic cleft. At higher concentrations, glutamate can also act as neurotoxin causing degeneration and death of neurons (Choi, 1992). This event is known as excitotoxicity and contributes to many chronic and acute neurodegenerative diseases. Therefore, glutamate homeostasis and the regulation of glutamate transporter abundance and function are a key element for the normal brain function.
High affinity, Na+-dependent glutamate transporters: localization, functional properties and topology
Molecular cloning has identified five different subtypes of Na+-dependent glutamate transporters, termed EAAT1–5 (excitatory amino acid transporters 1–5; nomenclature used for human subtypes). At present, two different nomenclatures are in use in the literature to indicate human and rodent isoforms (Table 5.1). However, the homologues show a high degree of interspecies conservation (>95%) and do not differ functionally. The gene names for the human transporter are as follows: EAAT3 or SLC1A1; EAAT2 or SLC1A2; EAAT1 or SLC1A3; EAAT4 or SLC1A4; EAAT5 or SLC1A5. The acronym SLC1 refers to ‘Solute Carrier family’ number 1 and A1 to family member number 1.
Localization
Immunohistochemistry studies revealed that the glutamate transporters EAAT1 and EAAT2 are localized to astroglial membranes that immediately oppose synaptic cleft regions of the neuropil.
- Type
- Chapter
- Information
- Neurodegenerative DiseasesNeurobiology, Pathogenesis and Therapeutics, pp. 57 - 64Publisher: Cambridge University PressPrint publication year: 2005
References
- 1
- Cited by